عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

‘Ahlam Alasr' Film Achieves Remarkable Success at Red Sea Festival Premiere

The film is produced by Tape Productions in collaboration with the Red Sea Fund, and is directed by Fares Godus, starring Sohayb Godus, Najm, Fatma AlBanawi, and Hakim Juma. SPA
The film is produced by Tape Productions in collaboration with the Red Sea Fund, and is directed by Fares Godus, starring Sohayb Godus, Najm, Fatma AlBanawi, and Hakim Juma. SPA
TT
TT

‘Ahlam Alasr' Film Achieves Remarkable Success at Red Sea Festival Premiere

The film is produced by Tape Productions in collaboration with the Red Sea Fund, and is directed by Fares Godus, starring Sohayb Godus, Najm, Fatma AlBanawi, and Hakim Juma. SPA
The film is produced by Tape Productions in collaboration with the Red Sea Fund, and is directed by Fares Godus, starring Sohayb Godus, Najm, Fatma AlBanawi, and Hakim Juma. SPA

Funded by the Saudi Cultural Development Fund, the film `Ahlam Alasr' attracted audiences at its premiere at the third annual Red Sea International Film Festival. The film’s premiere tickets were sold out within five days of the festival, and the movie garnered wide acclaim from both critics and the audience.
The film tells a unique story, exploring the depths of emotions and challenges faced by individuals in their daily lives. The story revolves around a retired football player who was famous before the internet came into existence. Along with his influencer daughter, he decides to seize an opportunity for revenge against those who wronged them. Together they embark on a toxic journey.
After the success of their first film “Shams Al-Ma'arif,” the Godus brothers impressed us again with their new film “Ahlam Alasr” and excelled in the film's direction, production, and acting. Director Fares Godus showcased precision in presenting the film, skillfully transporting the audience into a world of captivating details and events. The audience was also impressed and captivated by producer and lead character Sohayb Godus’ brilliant acting performance as well as Najm’s ability to inhabit the character she is playing.

“We are delighted with the support received from the Cultural Fund to bring our story to life and create something that lives up to the standards of the Saudi film sector. We are proud of the warm reception at the Red Sea International Film Festival, and we look forward to sharing this story with more audiences worldwide,” said Director Fares.

The film “Ahlam Alasr” is funded by the Cultural Development Fund through its Cultural Projects Incentive Program. Launched two years ago in partnership with the Quality of Life Program, the fund allocated a budget of SAR181 million to provide non-recoupable financing for projects in the cultural sectors, including film, to meet the needs of the cultural sector and contribute to its development.

The film, produced by Tape Productions in collaboration with the Red Sea Fund, directed by Fares Godus and starring Sohayb Godus, Najm, Fatma AlBanawi, and Hakim Juma, is expected to continue its screenings in other international film festivals. Its local cinema release will take place sometime next year, and the Godus brothers hope to sell international distribution rights soon to further solidify the position of Saudi film on the global stage.

Most Viewed

 
 
Varieties

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”